- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04646187
De-escalation of Anti-TNF Therapy in Inflammatory Bowel Disease (FREE)
De-escalation of Anti-TNF Therapy in Adolescents and Young Adults With IBD With Tight Faecal Calprotectin and Trough Level Monitoring
BACKGROUND/RATIONALE:
Treatment outcomes of patients with inflammatory bowel disease (IBD) have improved enormously during the past decade due to the use of anti-tumour necrosis factor (anti-TNF) therapy. As a result, 67 to 91% of paediatric patients and 66% of adult patients is still in sustained remission two years after the initiation of anti-TNF therapy. Prolonged use of anti-TNFs comes with disadvantages such as dose dependent susceptibility to infections and dermatological adverse effects. Preliminary, mostly uncontrolled studies suggest that dose reduction by dosing interval lengthening is a realistic option in a relevant proportion of patients with IBD, provided that intensive follow-up is applied.
OBJECTIVE:
To evaluate whether a faecal calprotectin (FC) guided strategy of anti-TNF dosing interval lengthening is non-inferior in maintaining remission in patients with IBD, compared with an unchanged dosing interval.
Study Overview
Status
Intervention / Treatment
Detailed Description
STUDY DESIGN:
International, multi-centre, prospective, partially randomised patient-preference trial.
STUDY POPULATION:
Study population: Eligible patients are aged 12-25 years with luminal Crohn's disease (CD) or ulcerative colitis (UC), who have three consecutive faecal calprotectin (FC) results in the target range (i.e. <250 µg/g for CD patients; <150 µg/g for UC patients) over a period of 6 months at study entry or recently confirmed endoscopic remission.
DE-ESCALATION STRATEGY:
In patients treated with adalimumab, the dosing interval will be lengthened from 2 to 3 weeks. In patients treated with infliximab, the dosing interval will be lengthened from 8 to 12 weeks. FC rapid tests will be performed every 4 weeks and rapid tests for anti-TNF trough levels will be performed every 12 weeks.
MAIN STUDY ENDPOINTS:
The primary outcome is the cumulative incidence of out-of-range FC results at 48 weeks follow-up. Secondary endpoints include time to get out-of-range FC results, cumulative incidence of anti-TNF associated adverse effects, proportion of patients progressing from out-of-range FC to loss-of-response and identification of predictors of successful de-escalation.
ETHICAL CONSIDERATIONS:
Patients with reduced anti-TNF exposure may have a higher risk of out-of-range FC results and, on the other hand, may benefit from fewer hospital visits or injections and possibly a decrease in adverse effects of anti-TNF therapy. Tight monitoring of FC levels (i.e. 4-weekly) will allow institution of re-escalation before the patient manifests clinical signs of relapse. This study cannot be conducted without the participation of minors and young adults, who typically have a short disease duration. Early treatment with anti-TNF agents possibly modifies the course of their disease, which makes provision for safe deescalation.
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Gent, Belgium, 9000
- Universitair Ziekenhuis Gent
-
Liège, Belgium, B-4000
- Centre Hospitalier Universitaire de Liege
-
Liège, Belgium
- Centre Hospitalier Regional de la Citadelle
-
-
-
-
-
Arnhem, Netherlands, 6816 AD
- Rijnstate Hospital
-
Eindhoven, Netherlands, 5623 EJ
- Catharina Hospital Eindhoven
-
Groningen, Netherlands, 9700 RB
- University Medical Center Groningen
-
Heerlen, Netherlands, 6419 PC
- Zuyderland Medical Center
-
-
-
-
-
L'Hospitalet De Llobregat, Spain, 08907
- Hospital Universitari de Bellvitge
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Aged 12-25 years
- Diagnosed with luminal Crohn's disease or ulcerative colitis
- Treated with either 8-weekly infliximab or 2-weekly adalimumab
- Current anti-TNF agent as first ever anti-TNF agent or prior anti-TNF agent discontinued for reason other than primary non-response or secondary loss-of-response
- No previous attempts to lengthen the dosing interval
- Three consecutive faecal calprotectin (FC) results in the target range (i.e. <250 μg/g for CD patients; <150 μg/g for UC patients) in the previous 6 months or confirmed endoscopic remission within 2 months before study entry (i.e. simple endoscopic score for Crohn's disease (SES-CD) <3 points for CD patients; ulcerative colitis endoscopic index of severity (UCEIS) ≤1 point for UC patients)
- Absence of symptoms associated with active IBD (judged by the local IBD-team)
- Written informed consent granted
Exclusion Criteria:
- Perianal fistula
- Presence of ileostomy or ileoanal pouch (as FC cut-off is not validated for small bowel faeces)
- Any inflammatory comorbidity, such as rheumatoid arthritis
- Current treatment with corticosteroids (prednisone or budesonide)
- Current pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention group
In patients treated with adalimumab, the dosing interval will be lengthened from 2 to 3 weeks.
In patients treated with infliximab, the dosing interval will be lengthened from 8 to 12 weeks.
Consists of two groups: Patients randomised to the intervention group and patients allocated to the intervention group based on preference.
|
Dosing interval lengthening from 8 to 12 weeks
Other Names:
Dosing interval lengthening from 2 to 3 weeks
Other Names:
|
No Intervention: Control group
Unchanged dosing interval.
Consists of two groups: Patients randomised to the control group and patients allocated to the control group based on preference.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
cumulative incidence of out-of-range fecal calprotectin results at 48 weeks follow-up
Time Frame: 48 weeks
|
Out-of-range FC results are defined as fecal calprotectin above the target range (i.e.
>250 μg/g for CD patients; >150 μg/g for UC patients) and at least 100 μg/g increase compared with the previous result, unless the previous result was already above the target range.
|
48 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to get out-of-range fecal calprotectin results
Time Frame: up to 48 weeks
|
The time from study baseline until the first out-of-range fecal calprotectin result
|
up to 48 weeks
|
Cumulative incidence of anti-TNF-associated respiratory infections and dermatological adverse effects at 48 weeks follow-up
Time Frame: 48 weeks
|
Dermatological adverse effect include skin infections, new-onset or worsening of psoriasis, psoriasiform lesions, eczema, acne and alopecia
|
48 weeks
|
Evolution of FC and anti-TNF trough levels in the first 16 weeks after reverting to previous dosing interval
Time Frame: Up to 48+16 weeks
|
Proportion of patients with return of FC levels to target range without switch to out-of-class biological
|
Up to 48+16 weeks
|
Proportion of patients developing loss-of-response in the first 16 weeks after reverting to the previous dosing interval
Time Frame: Up to 48+16 weeks
|
Loss-of-response is defined as the appearance of symptoms of active IBD in combination with persistent out-of-range fecal calprotectin results
|
Up to 48+16 weeks
|
Identification of predictors of successful de-escalation.
Time Frame: 48 weeks
|
Predictors of successful de-escalation will be assessed by calculating odds ratios with the use of univariate logistic regression analysis.
Candidate predictors with p<0.10 in univariate analysis will be selected for use in the multivariate analysis.
|
48 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patients' attitudes towards deprescribing anti-TNF agents
Time Frame: 48 weeks
|
We will use the revised Patients' Attitudes Towards Deprescribing (rPATD) questionnaire
|
48 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Patrick F van Rheenen, MD PhD, University Medical Center Groningen
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Gastrointestinal Diseases
- Gastroenteritis
- Colonic Diseases
- Inflammatory Bowel Diseases
- Crohn Disease
- Intestinal Diseases
- Colitis
- Colitis, Ulcerative
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Gastrointestinal Agents
- Dermatologic Agents
- Tumor Necrosis Factor Inhibitors
- Adalimumab
- Infliximab
Other Study ID Numbers
- 202000261
- 2020-001811-26 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Inflammatory Bowel Diseases
-
Centre Hospitalier Universitaire, AmiensFunding from DGOS (PHRC IR 2013 and PRME)CompletedPediatric Inflammatory Bowel DiseaseFrance
-
University of British ColumbiaCompletedInflammatory Bowel Disease 11Canada
-
University of ChicagoTerminatedInflammatory Bowel Disease (IBD)United States
-
University of Wisconsin, MadisonTerminatedInflammatory Bowel Disease (IBD)United States
-
Cedars-Sinai Medical CenterUnknownPediatric Inflammatory Bowel Disease
-
Assiut UniversityNot yet recruitingIBD-Inflammatory Bowel Disease
-
University of Wisconsin, MadisonCompletedInflammatory Bowel Disease (IBD)United States
-
Hull University Teaching Hospitals NHS TrustWellcome/EPSRC Centre for Interventional and Surgical Sciences, University...RecruitingInflammatory Bowel Disease 1United Kingdom
-
Icahn School of Medicine at Mount SinaiNorthwestern University; The Cleveland Clinic; University of California, Davis; RxHealt...RecruitingInflammatory Bowel Disease (IBD)United States
-
Nemours Children's ClinicNASPGHAN FoundationCompletedInflammatory Bowel Disease (IBD)United States
Clinical Trials on Infliximab
-
Onze Lieve Vrouwe GasthuisSanteonUnknown
-
Merck Sharp & Dohme LLCIntegrated Therapeutics GroupTerminatedRheumatoid Arthritis
-
Diakonhjemmet HospitalSouth-Eastern Norway Regional Health AuthorityCompletedRheumatoid Arthritis | Crohn's Disease | Ulcerative Colitis | Psoriatic Arthritis | Spondyloarthritis | Psoriasis ChronicNorway
-
PfizerCompleted
-
Centre hospitalier de l'Université de Montréal...Ottawa Hospital Research Institute; Maisonneuve-Rosemont Hospital; Niagara Health... and other collaboratorsRecruiting
-
NYU Langone HealthWithdrawnInflammatory Bowel Disease
-
Janssen Research & Development, LLCJanssen Biologics BVCompletedUlcerative ColitisUnited States, France, United Kingdom, Belgium, Switzerland, Israel, Canada, Australia, Netherlands, New Zealand, Austria, Germany, Denmark, Czechia, Argentina
-
BiocadCompletedAnkylosing SpondylitisRussian Federation, Belarus
-
PfizerCompletedPsoriasis Vulgaris | Pustular Psoriasis | Psoriasis Arthropathica | Erythrodermic PsoriasisJapan
-
Asan Medical CenterRecruitingCrohn Disease | Therapeutic Drug Monitoring | Infliximab | Perianal Fistula Due to Crohn's Disease | Magnetic Resonance Novel Index for Fistula Imaging in Crohn's Disease ScoreKorea, Republic of